Ganoderma lucidum KCCM 10045 which produces proteoglycan (G009) having effect of antitumor immunity
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 24, 1998
Grant Date -
N/A
app pub date -
Oct 4, 1995
filing date -
Dec 4, 1990
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
This invention relates to a strain, Ganoderma lucidum IY 009 which produces a proteoglycan G 009 possessed of antitumoral and immunostimulating effects, separated from the said cultured strain, containing: .beta.-glucose, .alpha.-glucose, galactose, .alpha.-mannose and fructose as saccharide components, and glycine, alanine, histidine, arginine, valine, aspartic acid, threonine, isoleucine, serine, leucine, glutamic acid, tyrocine, proline, phenylalanine and methionine as protein components. The Ganoderma lucidum IY 009 is deposited under accession number KCCM 10045.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully